Applying PBPK Modelling to Empower Translational Development for Radioligand Therapies (RLTs)

• Understanding the nuanced challenges with developing RLTs and the rationale behind applying PBPK models
• Exploring how PBPK models take note of compound and phyisological properties of mice versus human tissues to build an understanding of radiopharmaceutical distribution
• Leveraging PBPK data to optimize toxicity and efficacy of RLTs, leading to tumor growth inhibition

Speakers:

Giulia Tamborino

Principal Scientist - RLT Modeling & Simulation

Novartis